Compare BWMX & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMX | IRWD |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.4M | 663.6M |
| IPO Year | 2019 | 2009 |
| Metric | BWMX | IRWD |
|---|---|---|
| Price | $16.78 | $4.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $27.83 | $7.67 |
| AVG Volume (30 Days) | 80.4K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $18.17 | $57.95 |
| Revenue Next Year | $25.68 | $4.39 |
| P/E Ratio | ★ $12.54 | $26.03 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $7.00 | $0.55 |
| 52 Week High | $19.79 | $5.78 |
| Indicator | BWMX | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 54.78 |
| Support Level | $16.09 | $3.87 |
| Resistance Level | $19.43 | $4.50 |
| Average True Range (ATR) | 0.75 | 0.22 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 21.18 | 59.17 |
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.